This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 99/7/706    most recent 01.RES.0000243995.74395.f8v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arrell, D. K. Articles by Van Eyk, J. E. Search for Related Content PubMed PubMed Citation Articles by Arrell, D. K. Articles by Van Eyk, J. E. Related Collections Biochemistry and metabolism Energy metabolism Related Article

(Circulation Research. 2006;99:706.)
© 2006 American Heart Association, Inc.

Molecular Medicine

Proteomic Analysis of Pharmacological Preconditioning

Novel Protein Targets Converge to Mitochondrial Metabolism Pathways

D. Kent Arrell^*, Steven T. Elliott^*, Lesley A. Kane^*, Yurong Guo, Young H. Ko, Pete L. Pedersen, John Robinson, Mitsushige Murata, Anne M. Murphy, Eduardo Marbán, Jennifer E. Van Eyk

From the Department of Physiology (D.K.A., S.T.E., J.E.V.E.), Queen’s University, Kingston, Ontario, Canada; and Departments of Medicine (S.T.E., Y.G., M.M., E.M., J.E.V.E.), Biological Chemistry (L.A.K., Y.H.K., P.L.P., J.E.V.E.), Pediatrics (J.R., A.M.M.), and Biomedical Engineering (J.E.V.E.), The Johns Hopkins University, Baltimore, Md. Present address for D.K.A.: Division of Cardiovascular Diseases, Departments of Medicine, Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minn.

Correspondence to Jennifer E. Van Eyk, PhD, 602 Mason F. Lord Bldg, Center Tower, 5200 Eastern Ave, The Johns Hopkins University, Baltimore, MD 21224. E-mail jvaneyk1{at}jhmi.edu

Ischemic preconditioning is characterized by resistance to ischemia reperfusion injury in response to previous short ischemic episodes, a protective effect that can be mimicked pharmacologically. The underlying mechanism of protection remains controversial and requires greater understanding before it can be fully exploited therapeutically. To investigate the overall effect of preconditioning on the myocardial proteome, isolated rabbit ventricular myocytes were treated with drugs known to induce preconditioning, adenosine or diazoxide (each at 100 µmol/L for 60 minutes). Their protein profiles were then compared with vehicle-treated controls (n=4 animals per treatment) using a multitiered 2D gel electrophoresis approach. Of 28 significantly altered protein spots, 19 nonredundant proteins were identified (5 spots remained unidentified). The majority of these proteins are involved in mitochondrial energetics, including subunits of tricarboxylic acid cycle enzymes and oxidative phosphorylation complexes. These changes were not indiscriminate, with only a small number of enzymes or complex subunits altered, indicating a very specific and targeted affect of these 2 preconditioning mimetics. Among the changes were shifts in the extent of posttranslational modification of 4 proteins. One of these, the adenosine-induced phosphorylation of the ATP synthase ß subunit, was fully characterized with the identification of 5 novel phosphorylation sites. This proteomics approach provides an overall assessment of the cellular response to pharmacological treatment with adenosine and diazoxide and identifies a distinct subset of enzymes and protein complex subunit that may underlie the preconditioned phenotype.

Key Words: ATP synthase • phosphorylation • preconditioning • proteomics

Related Article:

Preconditioning Enters the Era of "Physiological Proteomics"

Richard A. Cohen and Mark E. McComb
Circ. Res. 2006 99: 663-665. [Full Text] [PDF]

This article has been cited by other articles:

				J. Feng, M. Zhu, M. C. Schaub, P. Gehrig, B. Roschitzki, E. Lucchinetti, and M. Zaugg Phosphoproteome analysis of isoflurane-protected heart mitochondria: phosphorylation of adenine nucleotide translocator-1 on Tyr194 regulates mitochondrial function Cardiovasc Res, July 2, 2008; (2008) cvn161v2. [Abstract] [Full Text] [PDF]

				E. Murphy and C. Steenbergen Mechanisms Underlying Acute Protection From Cardiac Ischemia-Reperfusion Injury Physiol Rev, April 1, 2008; 88(2): 581 - 609. [Abstract] [Full Text] [PDF]

				D. K. Arrell, N. J. Niederlander, R. S. Faustino, A. Behfar, and A. Terzic Cardioinductive Network Guiding Stem Cell Differentiation Revealed by Proteomic Cartography of Tumor Necrosis Factor {alpha}-Primed Endodermal Secretome Stem Cells, February 1, 2008; 26(2): 387 - 400. [Abstract] [Full Text] [PDF]

				A. Lopez-Campistrous, L. Hao, W. Xiang, D. Ton, P. Semchuk, J. Sander, M. J. Ellison, and C. Fernandez-Patron Mitochondrial Dysfunction in the Hypertensive Rat Brain: Respiratory Complexes Exhibit Assembly Defects in Hypertension Hypertension, February 1, 2008; 51(2): 412 - 419. [Abstract] [Full Text] [PDF]

				B. Page, R. Young, V. Iyer, G. Suzuki, M. Lis, L. Korotchkina, M. S. Patel, K. M. Blumenthal, J. A. Fallavollita, and J. M. Canty Jr Persistent Regional Downregulation in Mitochondrial Enzymes and Upregulation of Stress Proteins in Swine With Chronic Hibernating Myocardium Circ. Res., January 4, 2008; 102(1): 103 - 112. [Abstract] [Full Text] [PDF]

				D. H. Korzick, J. C. Kostyak, J. C. Hunter, and K. W. Saupe Local delivery of PKC{varepsilon}-activating peptide mimics ischemic preconditioning in aged hearts through GSK-3beta but not F1-ATPase inactivation Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2056 - H2063. [Abstract] [Full Text] [PDF]

				Y. Guo, Z. Fu, and J. E. Van Eyk A Proteomic Primer for the Clinician Proceedings of the ATS, January 1, 2007; 4(1): 9 - 17. [Abstract] [Full Text] [PDF]

				R. A. Cohen and M. E. McComb Preconditioning Enters the Era of "Physiological Proteomics" Circ. Res., September 29, 2006; 99(7): 663 - 665. [Full Text] [PDF]